MX2009000641A - Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns. - Google Patents

Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.

Info

Publication number
MX2009000641A
MX2009000641A MX2009000641A MX2009000641A MX2009000641A MX 2009000641 A MX2009000641 A MX 2009000641A MX 2009000641 A MX2009000641 A MX 2009000641A MX 2009000641 A MX2009000641 A MX 2009000641A MX 2009000641 A MX2009000641 A MX 2009000641A
Authority
MX
Mexico
Prior art keywords
gaba
chemical
group
conjugate
pain
Prior art date
Application number
MX2009000641A
Other languages
English (en)
Spanish (es)
Inventor
Ada Rephaeli
Irit Gil-Ad
Abraham Weizman
Abraham Nudelman
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of MX2009000641A publication Critical patent/MX2009000641A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009000641A 2006-07-17 2007-07-17 Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns. MX2009000641A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83119206P 2006-07-17 2006-07-17
US83119506P 2006-07-17 2006-07-17
PCT/IL2007/000903 WO2008010223A2 (en) 2006-07-17 2007-07-17 Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders

Publications (1)

Publication Number Publication Date
MX2009000641A true MX2009000641A (es) 2009-02-12

Family

ID=38621178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000641A MX2009000641A (es) 2006-07-17 2007-07-17 Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.

Country Status (11)

Country Link
US (3) US8222296B2 (enExample)
EP (1) EP2051735B1 (enExample)
JP (1) JP5192485B2 (enExample)
KR (1) KR20090048462A (enExample)
CN (1) CN101511388B (enExample)
AU (1) AU2007274583B2 (enExample)
CA (1) CA2659521A1 (enExample)
ES (1) ES2393933T3 (enExample)
IL (1) IL196538A0 (enExample)
MX (1) MX2009000641A (enExample)
WO (2) WO2008010222A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
CA2659521A1 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
EP2252578B1 (en) * 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
WO2010110916A2 (en) * 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
US8141697B2 (en) * 2009-04-03 2012-03-27 Ackley Machine Corporation Method and apparatus for transporting caplets
EP2480536B1 (en) * 2009-09-23 2014-08-13 The Regents of the University of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof
EP2509603A1 (en) 2009-12-09 2012-10-17 Biolinerx Ltd. Methods of improving cognitive functions
US8916610B2 (en) * 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
US9526718B2 (en) * 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
WO2014022807A2 (en) * 2012-08-03 2014-02-06 Alumend, Llc Compositions and methods of using the compositions for plaque softening
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
KR102510784B1 (ko) 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
WO2018199174A1 (ja) * 2017-04-25 2018-11-01 生化学工業株式会社 第３級アミン化合物又はイミン化合物－ポリマーコンジュゲートとその製造方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JP7441181B2 (ja) * 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態
WO2020062251A1 (en) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
WO2021257886A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2021257832A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CN119970650A (zh) 2020-10-05 2025-05-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN114452256A (zh) * 2021-12-31 2022-05-10 浙江大学 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法
CN115057865B (zh) * 2022-05-10 2023-03-31 国药集团工业有限公司 一种磷酸可待因半水合物的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944053A (en) * 1960-07-05 Uiiilcu
US3058979A (en) 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US2914528A (en) 1958-04-16 1959-11-24 Smith Kline French Lab Substituted phenothiazinyl trifluoro-methyl sulfones
NL227699A (enExample) * 1957-09-11 1900-01-01
US2969358A (en) 1958-12-08 1961-01-24 Searle & Co 2-chloro-10-phenothiazinecarbonylpiperazines
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3978216A (en) 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3956493A (en) 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
JPS6072868A (ja) 1982-10-04 1985-04-24 Fujisawa Pharmaceut Co Ltd 縮合複素環誘導体およびその製造法
US4629691A (en) 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
GB8413605D0 (en) 1984-05-29 1984-07-04 Gersan Ets Examining unfinished gemstone
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
EP0211905B1 (en) 1985-02-15 1990-10-03 The Broken Hill Proprietary Company Limited Classification of steel
WO1986004991A1 (en) 1985-02-15 1986-08-28 The Broken Hill Proprietary Company Limited Classification of steel
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
ES8707175A1 (es) 1986-06-13 1987-07-16 Inke Sa Procedimiento para la obtencion de la n-metil-3-(p-trifluorometilfenoxi)-3-fenilpropilamina
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH02128564A (ja) 1988-11-08 1990-05-16 Nec Corp 電話付きパーソナルコンピュータ
JP2801648B2 (ja) 1989-06-14 1998-09-21 日本化薬株式会社 ６―フルオロ―４―クロマノン―２―カルボン酸アミド又はエステルの製造法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3244793A (en) 1991-12-09 1993-07-19 Gem International Network, Inc. Computer imaging system for gemstones
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
AU6636996A (en) 1995-07-13 1997-02-10 Anormed Inc. 2-{2-(dimethylamino)ethyl}-8,8-dipropyl-2-azaspiro{4.5}decan edimaleate
CA2162532C (en) * 1995-11-09 2001-01-30 Dana J. Vanier Gemstone registration system
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5966673A (en) 1997-01-10 1999-10-12 Diamond Technologies, Inc. System and method for computerized evaluation of gemstones
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6020954A (en) * 1997-12-18 2000-02-01 Imagestatistics, Inc. Method and associated apparatus for the standardized grading of gemstones
US5983238A (en) 1997-12-26 1999-11-09 Diamond Id Gemstons identification tracking and recovery system
JP4002006B2 (ja) 1998-06-29 2007-10-31 日本電信電話株式会社 色校正装置、色校正方法、および色校正プログラムを記録した記録媒体
US20010024532A1 (en) 1998-09-21 2001-09-27 Malnekoff Peter J. Automated gemstone evaluation system
US6304853B1 (en) 1998-09-21 2001-10-16 Peter J. Malnekoff Automated gemstone evaluation system
IL134664A0 (en) 1999-10-29 2001-04-30 Diamond And Jewelry 4 U Ltd System for trade in precious gemstones
US6381510B1 (en) * 1999-11-19 2002-04-30 Eruggallery.Com Methods and apparatus for facilitating electronic commerce in area rugs
RO121085B1 (ro) * 1999-12-01 2006-12-29 Ucb, S.A., Utilizarea levetiracetamului, în tratamentul bolilor sistemului nervos central
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US8706645B2 (en) 2000-05-23 2014-04-22 David W. Hendry, Jr. System and method for appraising valuable items
US20020021439A1 (en) * 2000-08-07 2002-02-21 Derek Priestley Colour matching system
US7251619B2 (en) * 2000-09-01 2007-07-31 Garry Ian Holloway Computer implemented method, computer program product, and system for gem evaluation
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20030065586A1 (en) 2001-07-31 2003-04-03 Shaftel Keith L. Electronic commerce product pricing and selection system and method
US20030115079A1 (en) 2001-08-30 2003-06-19 Rapaport Martin M. Method of and system for ranking optimal values
CN100558365C (zh) 2001-09-27 2009-11-11 特拉维夫大学拉莫特有限公司 共轭的精神抑制药及其用途
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
CA2473536A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1500010A4 (en) 2002-01-25 2005-04-27 Menahem Sevdermish METHOD FOR THE DIGITAL COLOR GRADING OF JEWELS AND COMMUNICATION THEREFOR
US8046274B2 (en) 2002-01-25 2011-10-25 Menahem Sevdermish Method for digital color grading of gems and communication thereof
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
AU2004277400B2 (en) 2003-09-30 2009-01-22 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
AU2005281359A1 (en) * 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
TW200715156A (en) 2004-11-24 2007-04-16 Interdigital Tech Corp Intelligent information dissemination using a dynamic profile
US20090298814A1 (en) 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007050318A2 (en) 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CA2686155C (en) 2006-05-22 2016-11-15 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
CA2659521A1 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2011104637A2 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same

Also Published As

Publication number Publication date
WO2008010223A2 (en) 2008-01-24
AU2007274583B2 (en) 2012-11-01
US20100144869A1 (en) 2010-06-10
US20090304584A1 (en) 2009-12-10
US8222296B2 (en) 2012-07-17
US8377990B2 (en) 2013-02-19
CN101511388A (zh) 2009-08-19
WO2008010223A3 (en) 2008-03-20
EP2051735B1 (en) 2012-08-29
JP2009543858A (ja) 2009-12-10
WO2008010222A3 (en) 2008-04-10
AU2007274583A1 (en) 2008-01-24
CA2659521A1 (en) 2008-01-24
KR20090048462A (ko) 2009-05-13
IL196538A0 (en) 2009-11-18
WO2008010222A2 (en) 2008-01-24
ES2393933T3 (es) 2013-01-02
EP2051735A2 (en) 2009-04-29
US20130059910A1 (en) 2013-03-07
JP5192485B2 (ja) 2013-05-08
CN101511388B (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
AU2007274583B2 (en) Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
CN103025326B (zh) 治疗不安腿综合征的方法
US12036206B2 (en) Compositions and methods for pain relief
EP2252578B1 (en) Conjugates for treating neurodegenerative diseases and disorders
JP7066627B2 (ja) タンニン酸を含有する組成物及びその使用
JP2010518113A (ja) アンフェタミンおよび他の刺激薬の極性親水性プロドラッグ、およびそれらの製造方法および使用方法
JP2022538143A (ja) 新規な薬物動態学的特性を有するポリオキサゾリン－薬物コンジュゲート
US10905672B2 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
HUE032113T2 (en) Methylphenidate-prodrugs, processes of making and using the same
BR112019011640A2 (pt) composições que compreendem pró-fármacos de metilfenidato, processos de fabricação e uso das mesmas
JP2025023120A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
WO2011030205A1 (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
JP2019509321A (ja) 疼痛を処置するための組み合わせ
WO2025072583A1 (en) Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders
HK1178796B (en) Methods of treating restless legs syndrome
HK1179523B (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation

Legal Events

Date Code Title Description
FG Grant or registration